Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is the company that finally cracked metabolic dysfunction-associated steatohepatitis (MASH) — the fatty liver disease that affects 22 million Americans with progressive fibrosis. Rezdiffra (resmetirom) received FDA accelerated approval in March 2024, becoming the first and only approved therapy for non-cirrhotic MASH with significant fibrosis. The clinical signal was strong: 26 percent of patients achieved MASH resolution versus 9 percent on placebo, with parallel improvement in fibrosis. The commercial signal is now being tested in real-world prescribing.

At 523 dollars Madrigal market cap is 12 billion against Q1/2026 revenue of 348 million dollars (versus consensus 312) and roughly 1,400 net new patient starts per week. Annualized 2026 revenue trajectory is 1.6 billion dollars, with consensus 2027 at 2.4 billion. The stock is up from 265 low in 2024 panic when GLP-1 obesity drugs were thought to displace MASH therapeutics. That narrative has now reversed — GLP-1s improve weight but Rezdiffra remains the direct liver-targeted therapy, and prescribing data shows the combinations work synergistically rather than competitively.

Baker Bros Advisors holds 12.4 percent — the largest external shareholder and largest biotech focused fund. RA Capital Management 6.8 percent. Notable Q1/2026: Perceptive Advisors added 1.9 percent to existing position, taking total to 4.2 percent. Founder and CEO Bill Sibold owns roughly 1.2 percent and has not sold a single share since 2020. Bears: a short report from Spruce Point Capital in February 2026 questioned the durability of patient response, stock dropped 11 percent then recovered. Recent insider buys: Chief Medical Officer Bechtold purchased 2,500 shares at 480 dollars in April 2026 — modest size but rare in biotech executive ranks at this market cap.

At 523.69 dollars Madrigal trades on 42.3x forward 2026 earnings (consensus first profitability year), 5.0x EV/sales 2026, and 7.5x EV/sales on 2027 estimates. The 0.6 billion in net cash provides liquidity but not extensive runway given current burn for clinical trials and commercial buildout. The 29 percent upside to median target 674.36 reflects analyst confidence that 2027 trajectory holds — bull case 850 dollars (full 4.5B peak by 2029), bear case 320 dollars (commercial slowdown plus MAESTRO-AHF miss).

Position sizing for MDGL should respect that this is a 2-binary-catalyst stock: payer coverage trajectory and MAESTRO-AHF readout. Both 2026 events. The combined probability-weighted fair value lands roughly at current price (530), so the trade is execution-dependent rather than valuation-driven.

1. August 6, 2026: Q2/2026 results — first cross-check on whether 1,420 net new patient starts per week sustains; payer coverage trajectory update
2. Q4/2026: MAESTRO-AHF Phase 3 readout — Rezdiffra in compensated MASH cirrhosis; binary expansion catalyst
3. 2027: Pediatric MASH Phase 3 enrollment completion and atherosclerosis Phase 2 data — pipeline derisking events

Madrigal is the cleanest biotech specialty story in US large-cap biotech. The drug works, the market is large, the commercial machine is functioning, and the pipeline extends the franchise. The risk-reward is balanced rather than asymmetric because the valuation prices the bull case. I would take a 1 to 1.5 percent position with sizing discipline to respect the MAESTRO-AHF binary in Q4/2026. The drug is too well-validated to be a zero, but multiple compression on commercial slowdown is real. Watch the prior-authorization trajectory in Q2 reads — if PA jumps from 22 percent to 35 percent, recalibrate the thesis. If it stays flat, the bull case has runway.